Further, while combination ICT (anti-PD-1 and anti-CTLA-4) has been shown to be more effective than single agent ICT in melanoma (1, 2), combination therapy is also associated with a higher incidence of immune-related adverse events, including colitis, in cancer patients (79). The gene discussed is PDCD1; the disease is colitis.